Antibodies, which recognize viruses and proteins that the body has encountered before, have long gotten most of the credit ...

Red ginseng promotes macrophage activity by reducing the concentration of fatigue substances and promoting energy-generating ...

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide.

Seven students from among more than 300 entrants from the Loudoun County Public Schools Regional Science and Engineering Fair ...

Enlivex recently reported positive interim six (6) months efficacy data from the first stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe ...

Enlivex to receive Chinese patent for use of Allocetra as a potential treatment in patients with osteoarthritis: Nes-Ziona, Israel Wednesday, March 19, 2025, 10:00 Hrs [IST] Enliv ...

As of early 2025, tuberculosis cases are increasing in the U.S. This disease, often shortened to TB, causes significant lung damage and, if not treated, is almost always lethal.

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target dropped by HC Wainwright from $22.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage ...